Drugs Panel to weigh bringing all sterile drug products under central licensing amid contamination concerns

A proposal will soon be considered to centralize licensing for all sterile drug products. This move aims to tighten regulations on medicines prone to microbial contamination. Currently, only specific sterile medicines fall under central licensing authority. The proposal highlights fragmented existing frameworks and varying state inspection practices. Bringing all sterile products under central oversight will create a uniform regulatory system.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nUrDiCs
via IFTTT

Read More

QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell it

India's first approved dengue vaccine, QDENGA, will launch in the private market by mid-2027. Dr Reddy's Laboratories will distribute and promote the vaccine for individuals aged four to sixty. Takeda will retain rights for public market distribution as a future objective. QDENGA is a two-dose vaccine designed to protect against all four dengue virus serotypes. Dengue cases have significantly increased in India over the past two decades.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dGtOv2Z
via IFTTT

Read More

Health ministry issues advisory against unregulated stem cell therapies, restricts autism treatment to approved clinical trials

The Union health ministry issued an advisory against unregulated stem cell therapies. Therapeutic use of stem cells for autism is restricted to approved clinical trials. This advisory reiterates the existing framework governing stem cell research and therapy. It aligns with a Supreme Court ruling restricting unproven stem cell treatments. States and union territories must ensure strict compliance with the applicable framework.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/invwzoN
via IFTTT

Read More

Can wearable tech ease period pain? Curapod launches new device

Curapod has launched a new wearable device for menstrual pain management. This device utilizes red and near-infrared light wavelengths for pain relief. The wearable connects to a mobile application for personalized light dosage adjustments. Clinical evaluations indicate significant pain reduction for many users. The company is expanding its wearable technology into other pain management areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZYaf8nh
via IFTTT

Read More

Centre seeks NPPA report on high markups in hospital consumables

The Centre has requested a report from the NPPA regarding price discrepancies. Maharashtra FDA flagged significant gaps between trade prices and MRPs for hospital items. A survey revealed markups of over 2,800 percent on certain medical consumables. This situation may revive discussions on trade margin rationalisation for medical devices. The medical device industry supports calls for fair pricing and ethical practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tIavsxu
via IFTTT

Read More

US names India, China, Pakistan among drug transit, illicit drug-producing nations for FY27

The United States has designated India, China, and Pakistan as major drug producing or transit countries. This presidential determination covers twenty-three nations for fiscal year twenty twenty-seven. Afghanistan, Bolivia, Burma, and Colombia were separately identified for failing counternarcotics obligations. Inclusion on the list considers geographic and economic factors for drug production and transport. This designation does not necessarily reflect current government efforts or US cooperation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UOjoGXe
via IFTTT

Read More

Dr. Reddy's launches nivolumab biosimilar in India

Dr Reddy's Laboratories has taken a significant step in cancer care with the introduction of NIVORZ, a biosimilar of nivolumab. Designed to enhance immune response against a variety of cancers, this new treatment has received approval from the DCGI for twelve specific indications. By making this intravenous therapy available, Dr Reddy's aims to broaden access to affordable, high-quality cancer care options for patients in need.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T2NwOSC
via IFTTT

Read More